Top

Phage-Based Formulation Development

Active

Federal

Response Deadline08/31/2026, 09:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Defense → W6QK Acc Ccdc SttcView Agency

NAICS

541711 - Research and Development in BiotechnologyView NAICS

Place of Performance

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedAug 5

subcontract

Response DeadlineAug 31

Submission deadline

Response Deadline

08/31/2026, 09:00:00 PM UTCin 23 days

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Defense → W6QK Acc Ccdc Sttc

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Defense → W6QK Acc Ccdc Sttc

View Agency Profile

Office AddressN/A

ContactsNo contact information available

Full Description

Research and development of a stable phage cocktail formulation (≥1E8 PFU/ml) using specified buffers, stabilizers, preservatives, and moisturizers, including up to three formulation iterations.

Similar Contracts

Same NAICS industry code

NAICS: 541711

New

Federal

Dose Formulation and Compound Handling

National Institutes Of Health Olao

POSTED

DEADLINE

Housing Data Engineering & AI Analytics Tool DevelopmentThe contract seeks to design and build data tools, models, and dashboards aimed at identifying algorithmic bias in housing and lending decisions to support civil rights enforcement efforts. The work will involve developing advanced analytics capabilities that can evaluate automated systems for discriminatory patterns, ensuring compliance with fair housing and lending laws. The project requires expertise in data engineering, machine learning, and data visualization to create actionable insights for regulators and enforcement agencies. The effort is categorized as a subcontract under NAICS code 541711, indicating it falls under research and development in the physical, engineering, and life sciences. The solicitation was posted on August 7, 2026, with a response deadline of August 13, 2026, and is managed by the Civil Rights agency in Michigan. Although specific performance location details are not provided, the tools developed will serve statewide civil rights monitoring and enforcement activities, with the goal of enhancing transparency and accountability in automated decision systems affecting housing and credit access.

POSTED

DEADLINE

Integrated Phase I/II Clinical Trial DesignThe contract seeks the design and protocol development for an integrated Phase I/II clinical trial to evaluate ibogaine as a potential treatment for opioid use disorder, focusing on safety, optimal dosing, and therapeutic efficacy. The effort requires a comprehensive clinical framework that seamlessly merges the objectives of Phase I, which prioritizes dose escalation and toxicity profiling, with those of Phase II, which assesses preliminary effectiveness in reducing opioid dependence and withdrawal symptoms. The protocol must adhere to rigorous scientific and regulatory standards, incorporating appropriate patient selection criteria, monitoring procedures, endpoints, and risk mitigation strategies for a substance with significant pharmacological and safety considerations. The work is being pursued as a subcontract under the Advanced Research Projects Agency for Health, part of the Department of Health and Human Services, with a NAICS code indicating research and development in the life sciences. The solicitation was posted on August 5, 2026, and responses are due by October 15, 2026. The project is situated within a broader initiative to advance novel therapeutic interventions for the opioid crisis, requiring innovative trial design that balances exploratory research with clinical feasibility. There is no specified set-aside designation or location restriction for performance, indicating flexibility in execution while emphasizing scientific merit and regulatory alignment as key evaluation criteria.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

High-Throughput Yeast Two-Hybrid ScreeningA large-scale yeast two-hybrid screening project is being sought to identify protein-protein interactions between viral bait proteins and aphid prey libraries, encompassing all necessary laboratory procedures including yeast transformation and interaction assays. The effort is designed to enable high-throughput discovery of molecular connections critical to understanding viral infection dynamics in aphid hosts, with the goal of advancing agricultural pest and disease control strategies. This subcontract is designated as a Small Business Set Aside under NAICS code 541711, reserved exclusively for small business concerns, and is managed by the USDA Agricultural Research Service through its Albany Facility. The opportunity was posted on August 4, 2026, with a firm response deadline of August 28, 2026, and the performance location is specified as Ithaca, New York, with a zip code of 14853. The contract type and set-aside status emphasize support for small business participation in federally funded scientific research aimed at improving agricultural outcomes.

POSTED

DEADLINE

Aphid cDNA Prey Library DevelopmentThe contract involves the development of a normalized cDNA library from aphid RNA supplied by the government, specifically for use in yeast two-hybrid prey systems. The work includes reverse transcription of the RNA into complementary DNA and subsequent cloning procedures to generate a high-quality, representative library that enables effective protein-protein interaction screening. The project is designed to support biological research efforts by providing a standardized, scalable prey library that enhances the reliability and depth of interaction data in functional genomics studies. This subcontract is designated as a Small Business Set Aside under the NAICS code 541711, indicating it is reserved for small businesses engaged in research and development in the life sciences. The work is to be performed in Ithaca, New York, with a response deadline of August 28, 2026, and was posted on August 4, 2026. The contracting entity is the USDA Agricultural Research Service, Agricultural Facilities Management and Application Personnel Division, and the project is intended to advance USDA’s mission in agricultural biotechnology and pest research through innovative molecular tools.

POSTED

DEADLINE

Viral Bait Clone ConstructionThe contract involves the design and molecular cloning of viral protein bait constructs specifically for use in yeast two-hybrid systems, requiring comprehensive molecular biology expertise including codon optimization for host compatibility, precise plasmid insertion, and rigorous sequence validation to ensure accuracy and functionality. The work focuses on creating reliable protein baits that enable the study of virus-host protein interactions, which is critical for understanding pathogenic mechanisms and identifying potential therapeutic targets. All constructs must meet high standards of precision to support downstream functional assays in a controlled laboratory environment. The contract is designated as a Small Business Set Aside under NAICS code 541711 for scientific research and development, with performance to be carried out in Ithaca, New York, at the USDA ARS AFM APD facility. It was posted on August 4, 2026, and responses are due by August 28, 2026, with a clear emphasis on delivering technically robust and validated molecular reagents within the specified timeframe. The scope demands a high level of technical proficiency in molecular cloning, sequence analysis, and bioinformatics tools, with deliverables expected to support ongoing virology and host-pathogen interaction research funded by the U.S. Department of Agriculture.

POSTED

DEADLINE

In Vitro ADMET AssaysThe contract titled In Vitro ADMET Assays calls for the performance of high-throughput in vitro screening focused on metabolic stability, hepatotoxicity, CYP450 enzyme interactions, and cellular permeability to support early-stage drug development. These assays are critical for evaluating the absorption, distribution, metabolism, excretion, and toxicity profiles of potential therapeutic candidates, enabling informed decisions before advancing compounds into costly clinical stages. The work will be conducted to meet the specific needs of the National Institutes of Health NIDA under the Department of Health and Human Services, with performance expected to occur in Bethesda. This is a subcontract opportunity under NAICS code 541711, which classifies it as research and development in the physical, engineering, and life sciences. The solicitation was posted on August 3, 2026, with a response deadline of August 18, 2026, at 7:00 PM Eastern Time. There is no set-aside classification specified, and no point of contact or detailed office address is provided in the data. Interested parties must submit their proposals before the deadline to be considered for award, with the expectation that the selected contractor will deliver reliable, scalable, and scientifically rigorous ADMET data to guide NIDA’s research initiatives in drug development.

National Institutes Of Health Nida

POSTED

DEADLINE

Genotoxicity and Carcinogenicity TestingThe contract seeks to perform in vitro and in vivo assays to assess the mutagenic and carcinogenic risks of drug candidates, ensuring compliance with regulatory safety standards for pharmaceutical development. The work is critical for identifying potential genetic toxicity and cancer-causing properties early in the drug evaluation process to support regulatory submissions and public health safeguards. The solicitation is issued as a subcontract under the National Institutes of Health NIDA, part of the Department of Health and Human Services, with performance expected to take place in Bethesda. It falls under the NAICS code 541711 for research and development in the physical, engineering, and life sciences. The proposal must be submitted by August 18, 2026, with the opportunity posted on August 3, 2026. No set-aside provisions are specified, and the contract is open to qualified subcontractors with the technical capacity to deliver high-quality genotoxicity and carcinogenicity testing services.

National Institutes Of Health Nida

POSTED

DEADLINE

Safety Pharmacology (CNS, Cardiovascular, Pulmonary)The contract requires comprehensive safety pharmacology studies to evaluate adverse effects on the central nervous system, cardiovascular system, and pulmonary function, ensuring alignment with ICH safety guidelines. The work will involve detailed pharmacodynamic assessments to identify and characterize potential risks to major organ systems during early drug development, with a focus on identifying safety signals that could impact clinical translation. This subcontract, issued by the National Institutes of Health’s NIDA under the Department of Health and Human Services, is set to be performed in Bethesda and has a response deadline of August 18, 2026. The effort is classified under NAICS code 541711, indicating it pertains to research and development in the life sciences, and is aimed at supporting regulatory-compliant preclinical safety evaluations essential for pharmaceutical advancement.

National Institutes Of Health Nida

POSTED

DEADLINE

Toxicity Testing (Acute, Subacute, Subchronic, Chronic)The contract requires the performance of comprehensive toxicity testing in both rodent and non-rodent models to assess organ toxicity and establish safety margins for submission to regulatory authorities as part of an Investigational New Drug application. The scope includes acute, subacute, subchronic, and chronic studies designed to evaluate the potential adverse effects of pharmaceutical compounds across a range of exposure durations and dosages. The work must meet rigorous scientific standards to support regulatory filings and ensure the safety profile of investigational drugs is adequately characterized prior to human trials. This subcontract is issued under the National Institutes of Health, National Institute on Drug Abuse, within the Department of Health and Human Services, with the performance location specified as Bethesda. The North American Industry Classification System code 541711 identifies the work as research and development in the life sciences. The solicitation was posted on August 3, 2026, with a mandatory response deadline of August 18, 2026, at 7:00 PM. No set-aside provisions are specified, and the contract opportunity is open to eligible contractors capable of executing preclinical toxicology studies to support IND submissions.

National Institutes Of Health Nida

POSTED

DEADLINE

In Vivo Pharmacokinetic StudiesThe contract seeks to perform in vivo pharmacokinetic studies to assess the absorption, distribution, metabolism, and excretion of a drug candidate in both rodent and non-rodent species across multiple administration routes, with the goal of generating data to support an Investigational New Drug application. These studies will evaluate drug exposure over time to establish pharmacokinetic profiles critical for regulatory submission, requiring rigorous experimental design, appropriate species selection, and adherence to good laboratory practices. All work must be completed to ensure high-quality, reproducible results that meet FDA expectations for preclinical development. The solicitation is classified as a subcontract under NAICS code 541711, issued by the National Institutes of Health through the National Institute on Drug Abuse, part of the Department of Health and Human Services. Performance is expected to take place in Bethesda, and interested parties must submit their responses no later than August 18, 2026, at 7:00 PM. The opportunity was posted on August 3, 2026, and is open for competitive bidding with no specific set-aside designation. The contract does not provide a point of contact, and all inquiries must be directed through the official SAM.gov portal linked in the posting.

National Institutes Of Health Nida

POSTED

DEADLINE

Influenza Vaccine Clinical Trial ManagementThe contract pertains to the design and management of Phase I–III clinical trials for influenza vaccines, encompassing all critical aspects from protocol development and site selection to patient recruitment and regulatory reporting to the FDA. The work requires specialized expertise in infectious disease trials, with a focus on ensuring compliance with regulatory standards and timely submission of clinical data. The performance location is in Washington, DC, with a zip code of 20024, indicating the primary operational base for trial oversight and coordination. This is a subcontract under the Department of Health and Human Services, specifically managed by Barda – ASPR / DAAPPO / Barda DCMA, with a NAICS code of 541711 indicating scientific research and development services. The opportunity was posted on July 30, 2026, with a response deadline of August 15, 2026, at 9:00 PM ET. While no set-aside type or point of contact is specified, the emphasis on end-to-end clinical trial management suggests the subcontractor must possess a proven track record in vaccine development, regulatory engagement, and multi-site trial execution under federal health security initiatives.

Barda - Aspr / Daappo / Barda Dcma

POSTED

9 days ago

DEADLINE

in 7 days

View Details

More opportunities from Department Of Defense → W6QK Acc Ccdc Sttc

Same awarding agency

NAICS: 484220

New

Federal

Prototype Logistics and Cold Chain Delivery

Specialized Freight (except Used Goods) Trucking, Local

POSTED

DEADLINE

Regulatory Compliance and Toxicity Studies

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Resealable Pouch Packaging Supply

All Other Plastics Product Manufacturing

POSTED

DEADLINE

Topical Wipe Material Supply

Sanitary Paper Product Manufacturing

POSTED

DEADLINE

Stability and Safety Testing Services

Testing Laboratories and Services

POSTED

DEADLINE

REQUEST FOR WHITE PAPERS BAA TOPIC: Topic 13. Biotechnology, “Controlling polymicrobial environments as a strategy for defeating harmful organisms while promoting the growth of beneficial organisms”

Solicitation # W912CG-26-S-BIOTECH

The U.S. Army Combat Capabilities Development Command Soldier Center is soliciting white papers under Broad Agency Announcement W911QY-25-R-0023 to advance biotechnological research focused on controlling polymicrobial environments to suppress harmful organisms while fostering beneficial ones, with specific emphasis on developing phage-based hygiene wipes to prevent urinary tract infections in female Warfighters. The effort aims to design, optimize, and test a cosmetic-grade formulation that maintains bacteriophage viability under extreme thermal conditions—particularly at 45°C for four weeks—while being compatible with natural cellulosic wipes, resealable packaging, and regulatory standards under the Modernization of Cosmetic Regulation Act. The proposed formulation must include a phage cocktail at a minimum titer of 1E8 PFU/ml, a neutral pH buffer, preservatives effective at pH 7–8, stabilizers like polyvinyl alcohol, and moisturizing agents, all without compromising phage activity. Up to three formulation iterations are expected, culminating in the delivery of 100 prototype wipe packs—50 with active phage and 50 without—for field-relevant testing. Submission begins with a white paper, limited to five pages, detailing the technical approach, management structure, relevant past performance, and a rough order of magnitude cost estimate covering a 12-month base period with two optional 12-month extensions. Only white papers submitted electronically by 31 August 2026, 5:00 p.m. EDT, to the designated email address will be considered eligible for further invitation to submit a full proposal. Evaluation will prioritize scientific merit, management capability, alignment with Army mission needs, and cost-effectiveness, with feedback provided to submitters. Selection of white papers does not guarantee funding or a contract award, as decisions are contingent on budget availability and program priorities. The government reserves the right to cancel the solicitation at any time without obligation. Award mechanisms may include a contract, grant, or cooperative agreement, though a contract is the intended outcome. Formal proposals will only be requested from top-scoring white papers, and no further communication with government technical personnel is permitted after submission of a full proposal.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 days ago

DEADLINE

in 23 days

View Details